| abstract |
The invention provides a compound having a blood sugar-reduction effect, and the compound is demethyleneberberine. Demethyleneberberine is extracted from an in-vivo metabolite of natural drug berberine. A hyperglycemia model animal research shows that demethyleneberberine has good blood sugar-reduction effects, and after continuous administration for six weeks, obvious toxic or side effect is not produced. Through discovery of the use, a novel blood sugar-reduction drug can be produced and provides an optional drug for clinical treatment on diabetes and related diseases. |